Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment

BMC Psychiatry

Jorge Maurino³  Miguel A Gonzalez¹  Jaime L Galan⁴  Esteban Medina³  Mauro Garcia-Toro² 

[1] Quintiles, Madrid, Spain;Department of Psychiatry, Hospital Son Llatzer, Palma de Mallorca, Spain;AstraZeneca Medical Department, Madrid, Spain;Hospital Quirón, Málaga, Spain

关键词: Combination;    Switching;    Augmentation;    Antidepressant treatment;    Response;    Major depressive disorder;   

Others  :  1124288
DOI  :  10.1186/1471-244X-12-143

 received in 2012-04-30, accepted in 2012-09-13,  发布年份 2012

【 摘 要 】

Background

The aim of the study was to determine the most common pharmacological strategies used in the management of major depressive disorder (MDD) after an inadequate response to first-line antidepressant treatment in clinical practice.

Methods

Multicenter, non-interventional study in adult outpatients with a DSM-IV-TR diagnosis of MDD and inadequate response to first-line antidepressant medication. Multiple logistic regression analyses were performed to identify independent factors associated with the adoption of a specific second-line strategy.

Results

A total of 273 patients were analyzed (mean age: 46.8 years, 67.8% female). Baseline mean Montgomery-Asberg Depression Rating Scale total score was 32.1 (95%CI 31.2-32.9). The most common strategies were: switching antidepressant medication (39.6%), augmentation (18.8%), and combination therapy (17.9%). Atypical antipsychotic drugs were the most commonly used agent for augmenting antidepressant effect. The presence of psychotic symptoms and the number of previous major depressive episodes were associated with the adoption of augmenting strategy (OR = 3.2 and 1.2, respectively).

Conclusion

The switch to another antidepressant agent was the most common second-line therapeutic approach. Psychiatrists chose augmentation based on a worse patients’ clinical profile (number of previous episodes and presence of psychotic symptoms).

【 授权许可】

   
2012 Garcia-Toro et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wittchen HU, Jacobi F, Rehm J, et al.: The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychophamacology 2011, 21:655-679.
• [2]Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
• [3]Sinyor M, Schaffer A, Levitt A: The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry 2010, 55:126-135.
• [4]Connolly KR, Thase ME: If at first you don´t succeed. A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011, 71:43-64.
• [5]Anderson IM, Ferrier IN, Baldwin RC, et al.: Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008, 22:343-396.
• [6]Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E: Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol 2009, 24:133-138.
• [7]Rizvi AJ, Kennedy SH: The keys to improving depression outcomes. Eur Neuropsychopharmacology 2011, 21:S694-S702.
• [8]Sobocki P, Ekman M, Agren H, et al.: The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006, 60:791-798.
• [9]Sicras-Mainar A, Blanca-Tamayo M, Gutiérrez-Nicuesa L, et al.: Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting. Gac Sanit 2010, 24:13-19.
• [10]Grandes G, Montoya I, Arietaleanizbeaskoa MS, et al.: The burden of mental disorders in primary care. Eur Psychiatry 2011, 26:428-435.
• [11]Salvador-Carulla L, Bendeck M, Fernandez A, et al.: Costs of depression in Catalonia (Spain). J Affect Disord 2011, 132:130-138.
• [12]Papakostas GI: Managing partial response or nonresponse. Switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009, 6:16-25.
• [13]Papakostas GI, Shelton RC, Smith J, Fava M: Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007, 68:826-831.
• [14]Thase ME: Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry 2011, 56:317-323.
• [15]Souery D, Serretti A, Calati R, et al.: Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol 2011, 31:512-516.
• [16]Lobo A, Chamorro L, Luque A, Dal-Re R, Badia X, Baro E: Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales. Med Clin (Barc) 2002, 118:493-499.
• [17]Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville: Md: National Institute of Mental Health; 1976:218-222. [US Department of Health, Education, and Welfare publication (ADM) 76–338]
• [18]Kim HM, Zivin K, Ganoczy D, Pfeiffer P, Hoggatt K, McCarthy JF, et al.: Predictors of antidepressant initiation among U.S. veterans diagnosed with depression. Phamacoepidemiol Drug Saf 2010, 19:1049-1056.
• [19]Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF: Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000, 61:403-408.
• [20]Depression: the treatment and management of depression in adults (update, 2009). NICE: National Collaborating Centre for Mental Health commissioned by the National Institute for Health and Clinical Excellence. Available at: http://www.nice.org.uk/CG90 webcite
• [21]Rush AJ, Trivedi MH, Wisniewski SR, et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
• [22]Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, et al.: Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol 2012, 32:114-119.
• [23]Lam RW, Kennedy SH, Grigoriadis S, et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009, 117:S26-S43.
• [24]Villava E, Caballero L: Study on use and follow-up of treatment with antidepressants conducted by Primary Care physicians. SEMERGEN 2006, 32:427-432.
• [25]Fernandez-Meza A, Pinto-Meza A, Bellon JA, et al.: Is major depression adequately diagnosed and treated by general practitioners? Results from an epidemiological study. Gen Hosp Psychiatry 2010, 32:201-209.
• [26]Chang TE, Jing Y, Yeung AS, et al.: Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in Measurement-based Treatment (COMET) trial. Gen Hosp Psychiatry 2012, 34:105-112.
• [27]Thase ME: Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 2003, 64(suppl. 13):18-25.
• [28]Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy J, et al.: Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011, 72:1063-1071.